APT weighted imaging in diffuse gliomas.
Lucia NichelliMoritz ZaissStefano CasagrandaPublished in: BJR open (2023)
Amide proton transfer-weighted (APTw) imaging is a non-invasive molecular MRI technique with a wide range of applications in neuroradiology and particularly neuro-oncology imaging. More than 15 years of pre-clinical experiments and clinical studies have demonstrated that APTw metrics are reproducible and reliable, leading to large-scale clinical acceptance. At present, major vendors of MRI scanners provide APTw sequences upon request. However, most neuroradiologists are unfamiliar with this advanced MRI contrast, its related metrics, and its established added value to patient care. In this manuscript, we present the APTw contrast and illustrate its clinical potential for glioma patients, before and after tumor therapy. We also show common artifacts of APTw imaging and discuss potential limitations and future refinements. Our goal is to suggest how this emerging technique can aid in diffuse gliomas work-up.
Keyphrases
- contrast enhanced
- high resolution
- magnetic resonance
- magnetic resonance imaging
- end stage renal disease
- diffusion weighted imaging
- ejection fraction
- computed tomography
- newly diagnosed
- prognostic factors
- chronic kidney disease
- low grade
- risk assessment
- palliative care
- human health
- peritoneal dialysis
- climate change
- mass spectrometry
- smoking cessation
- single molecule
- patient reported